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Discovery of Picomolar Slow
Tight-Binding Inhibitors of -Fucosidase
cially available since 1996 for the treatment of type II
diabetes [1, 2]. As a consequence, the development of
potent glycosidase inhibitors has been shown extensive
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The Scripps Research Institute specific -fucosidases [14, 15]. For instance, an aber-
rant distribution of -fucosidase has been reported rele-10550 North Torrey Pines Road
La Jolla, California 92037 vant to inflammation [16], cancer [17, 18], and cystic
fibrosis [19, 20]. These enzymes have been recognized
as diagnostic markers for the early detection of colo-
rectal and hepatocellular cancers because of the pres-Summary
ence of -fucosidase in these patients’ sera [17, 18, 21].
On the other hand, potent -fucosidase inhibitors mayGlycosidase inhibitors have shown great medicinal
and pharmaceutical values as exemplified by the ther- be used to study their functions and develop potential
therapeutic agents.apeutic treatment of influenza virus and non-insulin-
dependent diabetes. We herein report the discovery We have recently developed a rapid generation of
libraries of compounds in microplates for high throughputof picomolar slow tight-binding inhibitors 2–5 against
the -fucosidase from Corynebacterium sp. by a rap- screening in situ without protecting group manipulation
and product isolation, and have identified the most po-id screening for an optimal aglycon attached to
1-aminomethyl fuconojirimycin (1). The time-depen- tent and selective inhibitors against the -fucosidase
from bovine kidney as well as Corynebacterium sp. [22].dent inhibition displays the progressive tightening of
enzyme-inhibitor complex from a low nanomolar Ki to This strategy is based on a rapid screening for an optimal
aglycon attached to the fuconojirimycin (FNJ)-basedpicomolar Ki* value. Particularly compound 2 with a
Ki* of 0.46 pM represents the most potent glycosidase structure that mimics the transition state of enzymatic
glycoside cleavage. The library screened for two -fuco-inhibitor to date. The effect of compound 3 on the
intrinsic fluorescence of -fucosidase is both time- sidases generated different groups of structures, indi-
cating that our approach is effective and simple for iden-and concentration-dependent in a saturation-type
manner, which is consistent with the initial formation tification of potent inhibitors that are enzyme specific
[22], and have little or no inhibition activity against otherof a rapid equilibrium complex of enzyme and inhibitor
(E•I), followed by the slower formation of a tightly glycosidase members (e.g., glucosidase, galactosidase,
and mannosidase) [22]. We report the discovery of slowbound enzyme-inhibitor complex (E•I*). The binding
affinity increases 3.5  104-fold from 1 (Ki  16.3 nM) and tight binding inhibitors of -fucosidase using this
approach. The introduction of a hydrophobic moietyto 2 (Ki* 0.46 pM). This work clearly demonstrates the
effectiveness of our combinatorial approach leading to to the iminocyclitol core not only resulted in the time-
dependent inhibition, but also greatly enhanced the in-the rapid discovery of potent inhibitors.
hibitory potency to give the Ki* value in the pM range.
Introduction
Results and DiscussionGlycosidases catalyze the cleavage of glycosidic bonds
associated with important biological activities, including
1-aminomethyl FNJ (1, Figure 1) [22] was used for diver-metabolic disorders [1, 2], viral and bacterial infection
sity-oriented reaction with various acids in the presence[3], tumor occurrence/metastasis [4, 5], glycoprotein
of (1H-benzotrizole-1-yl)-1,1,3,3-tetramethyluronium hexa-folding [6, 7] and function [8], and many other intercellu-
fluoorophosphate (HBTU, 1 equiv) and diisopropyl ethy-lar recognition processes. Some of these enzymes have
lamine (DIEA, 2 equiv) in DMF, followed by aqueousbeen considered as important targets for therapeutic
dilution and screening without purification [22], as showndevelopment. The neuraminidase inhibitor Tamiflu or osel-
in Figure 2. Several molecules were identified as potenttamivir phosphate, for example, has been prescribed to
and competitive inhibitors against the -fucosidase fromtreat the infection of influenza virus [9]. N-hydroxyethyl-
Corynebacterium sp. with the IC50 values in the low nMdeoxynojirimycin (namely Glyset or Miglitol), targeting
range. The screening was based on the detection ofthe intestinal disaccharidases [10], has been commer-
fluorescence emission of 4-methylumbelliferone at 465
nm in the presence of 4-methylumbelliferyl--L-fucopy-*Correspondence: chunhung@gate.sinica.edu.tw
3These authors contributed equally to this work. ranoside (or p-nitrophenol at 405 nm in the presence of
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Figure 3. Time-Dependent Inhibition of -Fucosidase by Com-Figure 1. Structures of Compounds 1–5
pound 2
p-nitrophenyl--L-fucopyranoside) [22]. It was observed
nation of Ki, Ki*and other numbers (Table 1, see equa-during the prolonged observation of enzyme inhibition
tions 2–5 for the details in the Experimental Procedures).assay that there was a time-dependent decrease in the
To access the reversibility of the enzyme-inhibitor com-reaction rate as a function of the inhibitor concentration.
plex, the -fucosidase was preincubated with each indi-Interestingly, nearly all the members of the library exhib-
vidual inhibitor (2–5) for 60 min at 20C to fully inactivateited, more or less, time-dependent slow tight-binding
the enzyme. Then, an excessive 105-fold dilution wasinhibition (e.g., the inhibition of compound 2, see Figure
made into a reaction mixture containing 100 M 4-meth-3). In a sharp contrast to the amide-forming reaction
ylumbelliferyl--L-fucopyranoside to monitor the recov-products, compound 1 is a reversible inhibitor with Ki
ery of activity (Figure 5). The result determined the ratevalue of 16.3 nM (Figure 4).
constant of k6 (rate of regain of activity from fully inhib-In order to investigate the inhibition mechanism, four
ited state) and corresponding t1/2 (half-life of E·I*), asFNJ derivatives (2–5) with different aglycon structures
shown in Table 1.and inhibitory potency were individually prepared and
In distinction from compound 1, all the coupling prod-purified. Analysis of the progress curves follows the
ucts 2–5 displayed time-dependent progressive inhibi-pattern in which an initial collisional complex (E·I) isom-
tion with a 696-, 225-, 23-, and 29-fold tightening (i.e.,erizes to a tighter complex (E·I*) according to equation
the values of Ki/Ki* in Table 1), respectively, from low1, where E stands for free enzyme, I is free inhibitor, E·I
nanomolar Ki to picomolar Ki* values. Especially com-is a rapidly forming preequilibrium complex, and E·I*
pound 2, superior to others in the-fucosidase inhibitionis the final enzyme-inhibitor complex [23, 24]. All the
with a Ki* of 0.46 pM, represents the most powerfulinhibitors were found to produce progressive tightening
glycosidase inhibitor yet described. As a consequence,of inhibition in a two-step manner, which was corrobo-
our rapid diversity-based synthesis and subsequent inrated by the fact that the inhibitor has a measurable
situ screening is able to promptly identify an optimaleffect on the initial rates before the onset of slow tight-
hydrophobic group for enhancement of the inhibition upbinding inhibition. Further examination of the progress
to 3.5  104-fold, when comparing the binding affinitycurves exhibited a time range where the initial rate of
of 1 (Ki  16.3 nM) and 2 (Ki*  0.46 pM). The resultingreaction did not deviate from linearity.
feature of slow-dissociating enzyme-inhibitor complex
is pharmacologically useful as exemplified by the
-lactamase inhibitors sulbactam and olivanate [25],
and the antihypertensive drug against angiotensin-con-
verting enzyme [26, 27].
The kinetic analysis of -fucosidase inhibition revealed
a two-step inhibition mechanism. To study whether this
(1)
isomerization is related to the conformational change in
-fucosidase due to binding of the inhibitor, the fluores-Fitting the measured data to this model allowed determi-
Figure 2. Rapid Diversity-Oriented Synthesis
in Microtiter Plates Followed by High-Through-
put Screening In Situ without Product Purifi-
cation
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Figure 4. Progress Curves for the Inhibition of -Fucosidase by
Figure 5. Determination of the Dissociation Rate Constant and Half-1-Aminomethyl FNJ (1)
Life for Regain of Catalytic ActivityThe figure shows that compound 1 is a reversible inhibitor.
The -fucosidase was preincubated with different concentrations
of compound 2 at 20C for 60 min. An aliquot was then removed,
diluted 105-fold, and assayed for the recovery of the enzyme activity.cence emission spectra of -fucosidase was analyzed
in the presence and absence of the inhibitor (3). The
enzyme exhibited an emission maxima (max) at 336 nm
as a consequence of the radiative enhancement of –* logs are also slow binding inhibitors [32]. Such time-
dependent inhibition was demonstrated as a conse-transition from the tryptophan residues, as shown in
Figure 6A. The binding of compound 3 resulted in a quence of relatively slow dissociation and association
of the inhibitor from and with the enzyme [32]. The bind-concentration-dependent increase of the fluorescence.
Titration of inhibitor 3 against the -fucosidase demon- ing was contributed by very large positive entropy,
which is very different from the thermodynamics ofstrated that the magnitude of the initial rapid fluores-
cence increase (F	F0) rose hyperbolically, which agreed 1-deoxynojirimycin [33]. On the other hand, the analysis
of our inhibitors was consistent with the two-step inhibi-well with the two-phase, slow tight inhibition (Figure 6B)
[28–30]. Furthermore, the effect of the inhibitor 3 on the tion mechanism, where the E·I complex isomerizes to
a tightly bound, slow-dissociating E·I* complex. This-fucosidase was also time dependent in a saturation-
type manner, displaying an exponential increase and conformational change induced in the -fucosidase was
supported by the measurement of intrinsic protein fluo-subsequent slow increase in fluorescence intensity. The
values of the derived first-order rate constants (kobs) at rescence.
In addition, Schramm et al. have established extensiveeach inhibitor concentration gave values of Ki and k5 of
1.17 nM and 0.057 s	1, respectively (see Experimental investigations of purine nucleoside phosphorylase (PNP)
inhibitors [34]. In their reports, immucillin-H and analogsProcedures for the details). These numbers are compa-
rable to those obtained from the previously mentioned are also slow-onset, tight-binding inhibitors [35]. The
crystal structure of PNP supports shorter distances ofkinetic analysis. Therefore, the consistency clearly links
the observed intrinsic protein fluorescence changes H-bonds in the enzyme-inhibitor complex than in the
Michaelis complex of enzyme-substrate, to be the causewith inhibitor binding.
According to the literature, the slow binding or slow- of the observed high affinity [34, 36]. The enhanced
inhibitory potency in our study is possibly due to theonset inhibition is prevalent among potent glycosidase
inhibitors, in particular iminocyclitols and certain indoli- additional hydrophobic interaction (

G  	16.2,
	13.4, 	7.8, and 	8.3 kJ/mol of compounds 2–5, re-zine alkaloids [23, 31]. The phenomenon was attributed
to the slow interchange between protein conformations. spectively) to bring closer the enzyme-inhibitor complex
via localized conformational change. The interpretationNevertheless, the previous studies by Bols et al. indi-
cated that 1-azafagomin and hydrazine-containing ana- seems to agree well with our observation that almost
Table 1. Inhibition Constants of Compounds 1–5 against the -Fucosidase from Corynebacterium sp.
1 2 3 4 5
Ki (nM) 16.3  2.5 0.32  0.02 1.24  0.23 1.15  0.18 1.37  0.33
Ki* (pM) — 0.46  0.03 5.5  0.2 49  5 47  6
Ki/Ki* — 696 225 23 29
k5 (s	1) — 2.7  10	1 7.2  10	2 5.1  10	2 9.9  10	2
k6 (s	1) — 3.9  10	4 3.2  10	4 2.1  10	3 3.3  10	3
t1/2 (min) — 30 36 5.5 3.5

G1 (kJ/mol)a 	44.4 	54.2 	50.8 	51.0 	50.6

G2 (kJ/mol)b — 	70.4 	64.2 	58.8 	58.9
a Free energy change to give E·I complex (see Equation 1).
b Free energy change to give E·I* complex (see Equation 1).
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study demonstrates that an additional high-affinity
binding component, especially the one with hydropho-
bic nature, connected to a transition-state mimic, can
be rapidly identified. The slow and tight binding be-
havior observed in this study may be caused by the
hydrophobic group to induce conformational change
to further augment the inhibitory potency. As a conse-
quence, with the incorporation of an optimized agly-
con to 1-aminomethyl FNJ (1, Ki  16.3 nM), the re-
sulting inhibitor 2 is the most potent glycosidase
inhibitor with a Ki* of 0.46 pM. Work is in progress to
determine the structure of the enzyme-inhibitor com-
plex to further understand the mechanism of inhibition.
The slow-releasing feature of the inhibition process
also provides a new direction in drug design.
Experimental Procedures
Materials and Reagents
Analytical TLC was performed on precoated plates (Merck, silica
gel 60F-254). Silica gel used for flash column chromatography was
Mallinckrodt Type 60 (230–400 mesh). Reagents of the highest purity
were purchased from Aldrich, Sigma, Acros, and Novabiochem.
1-Aminomethyl FNJ (1)
1H NMR (400 MHZ, D2O)  3.81 (d, J  2.4 Hz, 1H, H4), 3.57 (dd, J 
2.4, 9.6 Hz, 1H, H3), 3.49 (t, J  9.6 Hz, 1H, H2), 3.34 (dd, J  5.3,
13.2 Hz, 1H, CH2), 3.05 (dd, J  7.0, 13.2 Hz, 1H, CH2), 2.90 (q, J 
6.7 Hz, 1H, H5), 2.79 (ddd, J  5.3, 7.0, 9.6 Hz, 1H, H1), 1.12 (d, J 
6.7 Hz, 3H, H6 (CH3)). 13C NMR (100 MHZ, D2O)  75.19, 72.63, 71.07,
57.09, 53.13, 41.88, 16.66.
Typical Procedure of Amide-Forming Reaction
(Synthesis of Compound 5)
Figure 6. Fluorescence Emission Spectra and Effect of Concen-
To a solution of a free amine 1 (34 mg, 0.193 mmol) and 2-phenyl-
tration
4-quinolinecarboxylic acid (52.9 mg, 0.212 mmol) in 2 ml dry DMF
(A) Steady-state fluorescence emission spectra of -fucosidase as was added HBTU (80.4 mg, 0.212 mmol) and DIEA (73.8 L, 0.424
a function of compound 3. mmol) at 25C under atmospheric pressure of N2. The reaction mix-
(B) Effect of compound 3 concentration on the tryptophanyl fluores- ture was stirred for 30 min and then quenched by addition of brine
cence of -fucosidase. and extracted with EtOAc. The organic layer was washed with 1 N
HCl, saturated aqueous NaHCO3, and brine, dried over MgSO4, fil-
tered, and concentrated in vacuo. The resulting residue was purified
by flash chromatography with CHCl3/MeOH (3/1, Rf  0.37) to giveall the amide-forming reaction products in Figure 2 (the
the desired product 5 (69 mg) in 88% yield.coupling reaction of 1 with various acids) were slow
tight-binding inhibitors, i.e., a hydrophobic domain near
Compound 2the active site may exist to facilitate such interaction.
The synthesis was carried out in the same manner as previouslyInterestingly, the same library of FNJ derivatives in
described. Yield 90%, []25D   6.2 (c 1.0, MeOH). 1H NMR (400Figure 2 shows only reversible inhibition against the
MHZ, MeOH-d4)  7.49 (d, J  8.0 Hz, 1H), 7.25 (d, J  8.0 Hz, 1H),
bovine kidney -fucosidase, implying a different struc- 7.03–6.91 (m, 3H), 3.74 (d, J  2.8 Hz, 1H, H4), 3.57 (t, J  9.6 Hz,
tural arrangement surrounding the enzyme active site. 1H, H2), 3.48–3.44 (m, 1H, H1), 3.39 (dd, J  9.6 Hz, J  2.8 Hz, 1H,
(Recently, Bourne and Henrissat et al. reported the struc- H3), 3.24–3.23 (m, 1H, H1), 3.19 (q, J  6.7 Hz, 1H, H5), 3.01 (t, J 
7.6 Hz, 2H), 2.84 (ddd, J  11 Hz, J  6.2 Hz, J  2.7 Hz, H1), 2.56tural determination of Thermotoga maritima -fucosi-
(t, J  7.6 Hz, 2H), 1.29 (d, J  6.7 Hz, 3H). 13C NMR (100 MHZ,dase [14] More insight can be revealed from the se-
MeOH-d4)  178.37, 138.22, 128.64, 123.28, 122.48, 119.72, 119.39,quence alignment among different species as well as
114.92, 112.42, 75.18, 71.36, 67.99, 61.47, 59.32, 40.13, 39.01, 22.67,
the molecular modeling.) Our observation seems to be 15.30. ESI-MS: m/z 348 (M  1).
consistent with the report from Ganem and coworkers
that very similar enzymes can be distinguished by the
Compound 3 (Diasteromers)
introduction of a charge or hydrophobic feature to inhibi- The synthesis was carried out in the same manner as previously
tors [37, 38]. mentioned. Yield 89%, 1H NMR (400 MHZ, MeOH-d4)  7.34–7.15
(m, 10H), 3.65 (d, J  2.8 Hz, 2H), 3.49–3.25 (m, 8H), 3.15 (d, J 
11.1 Hz, 2H), 2.90–2.81 (m, 2H), 2.62–2.50 (m, 4H), 1.91–0.88 (m,Significance
22H). 13C NMR (100 MHZ, MeOH-d4)  178.00, 177.88, 141.59, 141.53,
129.57, 129.39, 129.35, 129.33, 128.22, 128.20, 76.72, 76.67, 73.34,
A simple and efficient approach has been developed 73.18, 70.41, 70.21, 61.26, 61.18, 60.30, 60.27, 55.03, 55.99, 44.36,
for quick identification and optimization of -fucosidase 44.21, 41.58, 41.49, 32.68, 32.60, 31.92, 31.89, 26.36, 26.33, 26.04,
26.01, 17.32, 17.16. ESI-MS: m/z 363 (M  1).inhibitors, including slow tight-binding inhibitors. The
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Compound 4 using the equations as follows: V0  Vmax [S]/(Km (1  [I]/Ki)  [S])
and VS  Vmax [S]/(Km (1  [I]/Ki*)  [S]).The synthesis was carried out in the same manner as previously
mentioned. Yield 86%, []25D   4.8 (c 1.0, MeOH). 1H NMR (400 The rate constant k6, for the dissociation of the second enzyme-
inhibitor complex can be also measured directly from the inhibitorMHZ, MeOH-d4)  7.49–7.03 (m, 4 H), 3.92–3.84 (m, 2H), 3.88 (d, J 
2.8 Hz, 1H), 3.82 (t, J  10 Hz, 1H), 3.60 (dd, J  2.8, 9.6 Hz, 1H), release studies as described below.
3.47 (q, J  6.6 Hz, 1H), 3.35 (dd, J  1.6, 3.2 Hz, 1H), 3.25 (ddd,
J 3.0, 6.2, 10.0 Hz, 1H), 1.44 (d, J  6.7 Hz, 3H). 13C NMR (100 MHZ, Dissociation of E·I* Complex
MeOH-d4) 165.7, 160.8, 158.4, 135.3, 114.5, 114.2, 107.0, 106.8, 105.2, The E·I* complex of the -fucosidase and inhibitor (2, 3, 4, or 5)
75.3, 71.5, 68.2, 61.7, 56.5, 40.4, 15.3. ESI-MS: m/z 338 (M  1). was prepared by incubation of 10 M -fucosidase with different
concentrations of inhibitor (125 and 150 M) at 20C for 60 min. An
Compound 5 aliquot of the incubation mixture was withdrawn and diluted 105-
[]25D   1.2 (c 1.0, MeOH). 1H NMR (400 MHZ, MeOH-d4)  8.35– fold in 200 l of 50 mM HEPES buffer (pH 8.0) containing 100 M
7.50 (m, 10 H), 3.99 (dd, J  3.0, 15.0 Hz, 1H), 3.93–3.80 (m, 3H), 4-methylumbelliferyl--L-fucopyranoside as the assay substrate.
3.55 (dd, J  1.8, 9.3 Hz, 1H), 3.44 (q, J  6.7 Hz, 1H), 3.32 (ddd, Recovery of the enzyme activity was measured by monitoring the
J  3.0, 6.7, 10.2 Hz, 1H), 3.24 (dd, J  1.5, 3.2 Hz, 1H), 1.36 (d, J  emission at 465 nm based on an excitation wavelength of 360 nm.
6.7 Hz, 3H). 13C NMR (100 MHZ, MeOH-d4)  170.6, 158.2, 146.9, 146.1, The resulting data was transferred into the software KaleidaGraph
137.6, 133.3, 132.3, 130.5, 129.7, 129.5, 127.9, 127.1, 125.2, 119.8, 75.3, and fitted by equation 2 to determine the dissociation constant k6
71.5, 68.5, 60.7, 56.6, 40.9, 15.3. ESI-MS: m/z 408 (M  1). and t1/2 (half-life of the E·I* complex).
Synthesis and Inhibition Assay of -Fucosidase In Situ Fluorescence Analysis of the Enzyme-Inhibitor Complex
The synthesis of amide derivatives in microplates was carried out The change of -fucosidase intrinsic fluorescence upon the addition
as described previously [22]. Assay mixtures of 200 l contained of compound 3 was monitored using an F-4500 fluorescence spec-
50 mM HEPES (pH 8.0), 0.1% BSA (by weight), 50 M 4-methylum- trometer (Hitachi Co., Japan). The emission spectra were recorded
belliferyl--L-fucopyranoside, and inhibitor (final concentrations: from 300 to 450 nm upon the excitation of -fucosidase at 285 nm.
1.0–3.0 nM). The -fucosidase (0.2 nM) was added to initiate inhibi- The fluorescence spectra of 0.44 M -fucosidase in 50 mM HEPES
tion assays. The emission at 465 nm was monitored using an excita- buffer (pH 8.0) at 20C were measured before and after addition of
tion wavelength of 360 nm to measure the release of fluorescent compound 3 (Figure 6A). The fluorescence changes (F	F0) were
4-methylumbelliferone at 20C. When 200 M p-nitrophenyl--L- plotted against the inhibitor concentration at the emission wave-
fucopyranoside was used as the substrate, the absorption at 405 length of 336 nm (Figure 6B).
nm was measured for the release of p-nitrophenol. The rate constants (kobs) for the time-dependent increase in intrin-
The resulting data were analyzed and determined to follow the sic fluorescence at each inhibitor concentration were calculated by
aforementioned slow binding inhibition pattern (equation 1). The computer fitting of the data to a first-order equation of the form,
kinetics can be described according to an integrated equation y  a  b exp(	kobs) using the software KaleidaGraph. These kobs
(equation 2), in which V0 and VS are the initial and the steady-state values were then fitted to the equation kobs  k5 [I]/(Ki  [I]) to give
rates, k is the apparent rate constant for establishing the steady- computer-calculated values of Ki and k5.
state equilibrium, and P is amount of product accumulated during
a period of time t.
Supplemental Data
1H NMR spectra of compounds 2–5 are available online at http://
P  VS · t  (V0 	 VS)
(1 	 e	kt )
k
(2) www.chembiol.com/cgi/content/full/11/9/1301/DC1.
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